Skip to main content
SpringerLink
Log in

Delayed-Release Multi Matrix System (MMX™) Mesalazine in Ulcerative Colitis

A Viewpoint by Åke^Nilsson

  • Adis Drug Profiles
  • Guest Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007 Jan; 132(1): 66–75

    Article  PubMed  CAS  Google Scholar 

  2. Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 2005 May; 11(5): 421–7

    Article  PubMed  Google Scholar 

  3. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007 Jan; 5(1): 95–102

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medicine, Department of Clinical Sciences, Lund University Hospital, Lund, Sweden

    Åke Nilsson

Authors
  1. Åke Nilsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nilsson, Å. Delayed-Release Multi Matrix System (MMX™) Mesalazine in Ulcerative Colitis. Drugs 67, 2643 (2007). https://doi.org/10.2165/00003495-200767170-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767170-00011

Search

Navigation